Cipla Ltd.Margin Pressure Amid Transition, US Pipeline Pivotal

Cipla reported Q3 FY26 revenue of ₹7,074 crores, remaining flat year-on-year as generic Revlimid completion and Lanreotide supply disruption offset growth momentum.

EBITDA margin compressed to 17.7%, leading management to revise full-year FY26 guidance to approximately 21% from earlier expectations. The India business demonstrated resilience with robust 10% growth, driven by double-digit performance across key therapies including respiratory, anti-diabetes, cardiac, and urology, while chronic mix strengthened to 62.3%. US revenue declined to $167 million due to partner Pharmathen's manufacturing halt affecting Lanreotide supply until H1 FY27.

Strategic investments remain elevated with R&D at 7% of revenue to support a differentiated pipeline. Management emphasized upcoming launches including generic Victoza in Q4 FY26, four respiratory assets including generic Advair, and three additional peptide products in FY27 as critical growth drivers. India portfolio strengthening continues through the Galvus acquisition for ₹1,100 crores, Inzpera acquisition for pediatrics, and innovative launches like Afrezza and Yurpeak, positioning Cipla for sustainable long-term growth despite near-term margin pressures.